
BMY • NYSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold BMY in your mock portfolio yet.
With a PE of 18.0 and EPS of 2.97, Bristol-Myers Squibb is trading at a valuation that suggests neither clear distress nor strong growth enthusiasm. The earnings profile appears stable but not rapidly expanding, implying the market is pricing in moderate, mature-pharma growth rather than a high-growth story.
The stock is trading modestly above its 200-day moving average and has risen 2.5% over the last month, suggesting a mild positive trend but not a strong breakout. An RSI of 48.43 is essentially neutral, indicating neither overbought nor oversold conditions.
Alternative data show flat demand-side digital engagement and a notable decline in job postings, which can imply slower expansion or cost discipline. Social media followership is largely stagnant with only modest growth on YouTube and LinkedIn, suggesting limited incremental brand or engagement momentum.
Overall, Bristol-Myers Squibb’s setup appears neutral: valuation and earnings suggest a stable, mature business, while technicals show modest strength without a clear bullish breakout. Weak-to-flat alternative data slightly temper the outlook, pointing more toward a steady, range-bound profile than a strong upside or downside conviction.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Key moves vs recent baseline (last day / last week)
Plain-English summary of the biggest drivers (informational)
Potential risk factors to review
Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.
Reassess your thesis if any of these occur: